• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

FDA Questions Efficacy of Merck-AstraZeneca’s Lynparza Ahead of Adcomm

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Apr 27, 2023 at 11:12: PM
via In briefing documents published ahead of the Oncologic Drugs Advisory Committee (ODAC) meeting, FDA staffers argued that Merck and AstraZeneca’s Lynparza (olaparib) is effective in only a subset of patients with metastatic castration-resistant prostate cancer (mCRPC).

article source
 




Top Bottom
Back
Quote